Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3211854 | Journal of the American Academy of Dermatology | 2007 | 54 Pages |
Abstract
The introduction of a number of biologic therapies into the market has revolutionized the practice of dermatology. These therapies include interferons, intravenous immunoglobulin, infliximab, adalimumab, etanercept, efalizumab, alefacept, and rituximab. Most dermatologists are familiar with the Food and Drug Administration–approved indications of these medications. However, numerous off-label uses have evolved. As part 1 of a 2-part series, this article will review the literature regarding the off-label uses of the interferons and intravenous immunoglobulin in dermatology.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
David I. Smith, Pooja M. Swamy, Michael P. Heffernan,